Tag: Smoking Cessation

Cytisinicline well tolerated with only 2.9 percent of participants discontinuing due to an adverse event

Reduced risk seen for all CVD events, respiratory system disease events, hospitalization due to CVD or RSD, adverse birth outcomes

Adjusted prevalence of nicotine dependence was lower for those aged 18 to 25, 26 to 34, 35 to 49 versus those aged 50 and older

No significant difference in verified seven-day abstinence seen by treatment group among Black adults who smoke daily

Decreases in depression, anxiety seen, particularly in people with history of mental illness

Symptom burden is not associated with interest in quitting, likelihood of quitting, or odds of quit attempts

For ever smokers, log2-transformed years since smoking cessation before diagnosis associated with significantly lower mortality

App use tied to higher six-month biochemically verified sustained abstinence rate

Greatest benefit seen for former smokers who quit >10 years before diagnosis

However, early electronic cigarette quitters plus stable cigarette use was the most common trajectory in 41.6 percent of participants